Skip to main content
Equibles
SPRY logo

SPRY · ARS Pharmaceuticals, Inc. · Metrics

Track SPRY — free

Use SPRY with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SPRY.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$4.01 -0.03 (-0.62%)
Russell 2000 member Rebalance outlook locked
Market Cap
$397.79M
Shares
99.45M
Volume · Oct 26 557.86K Avg daily vol (3M) 1.74M

SPRY metrics

86 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$4.03
Market cap
$397.79M

Price action

20 metrics
Price change (1W)
+0.2%
Price change (30D)
-2.4%
Price change (3M)
-32.2%
Price change (6M)
-51.4%
Price change (YTD)
-65.4%
Price change (1Y)
-58.2%
Trailing year
Price change (5Y)
-56.2%
52-week high
$13.06
52-week low
$3.93
Change from 52-week high
-69.1%
Change from 52-week low
+2.5%
Annualized volatility
74.5%
Annualized volatility (3M)
71.4%
Beta
1.7
RSI (14D)
41.4
Price vs SMA 50
-16.2%
Price vs SMA 200
-46.9%
Avg volume (3M)
1.74M
Relative volume
0.9
Average dollar volume
$8.85M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
99.45M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
3.0×
reciprocal yield 33.1%
EV / EBITDA
—
EV / EBIT
—
P / sales
3.4×
reciprocal yield 29.2%
P / book
32.0
reciprocal yield 3.1%
FCF yield
-49.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-53.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
9,899.1×
reciprocal yield 0.0%
EV / revenue historical average (5Y)
8,330.6×
reciprocal yield 0.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
—
Operating margin
-185.0%
Trailing 12 months
Net margin
-184.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$216.27M
Net income (TTM)
−$215.43M
Trailing 12 months
Diluted EPS (TTM)
$-2.17
FCF margin
-168.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.18
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-2.18
EBITDA per diluted share (TTM)
$-2.17
Net income per diluted share (TTM)
$-2.17
Operating cash flow per diluted share (TTM)
$-1.98
Free cash flow per diluted share (TTM)
$-1.98
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.15
Stock compensation per diluted share (TTM)
$0.32
Book value per share
$1.15

Growth

11 metrics
Revenue growth YoY
+114.2%
Year over year
Net income growth YoY
-2,241.8%
Revenue (TTM)
$116.93M
Trailing 12 months
EPS growth YoY
-2,275.0%
Shares change YoY
+1.0%
Year over year · more shares
Revenue CAGR (3Y)
+300.1%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-1,721.8%
Return on assets
-86.3%
Debt / equity
7.7
Current ratio
3.5
EBITDA (TTM)
−$214.65M
Free cash flow (TTM)
−$196.60M
Quick ratio
3.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$47.17M
Latest balance sheet
Cash & equivalents
$8.16M
Total assets
$249.50M
Total debt
$96.68M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$196.41M
Capital expenditures (TTM)
$197,000
R&D (TTM)
$15.23M
SG&A (TTM)
$284.49M
Stock compensation (TTM)
$31.24M
R&D / revenue
13.0%
Stock compensation / revenue
26.7%

Ownership (13F)

9 metrics
13F filers
208
13F filer change QoQ
+3
Institutional ownership
91.5%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
56.3%
Private-fund adviser ownership
55.3%
Active holders' share change QoQ
-4.9%
Holder tenure
11.2
Price vs estimated holder cost
-13.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.2%

Short interest

3 metrics
Short interest
21.3%
Latest settlement · 16.1 days to cover
Days to cover
16.1d
Short-squeeze score
77 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1671858 CUSIP 82835W108 13F (30d) 21 filings 21 filers Visit website Investor relations